Ulf Persson
Professor | Ph.D. | CEO
Work areas
Ulf Persson, PhD, is Professor in Health Economics at the Institute of Economic Research, School of Economics and Management, Lund University and Chief Executive Officer at the Swedish Institute for Health Economics (IHE).
Ulf Persson has more than 25 years research experience in the development and application of economic evaluation methods in health care, with particular regard to the introduction and utilization of medical technologies.
His main research areas are health economics, pharmaceutical economics, economic evaluations, and transport economics. Projects and publications include cost-effectiveness studies, cost-of-illness studies, willingness-to-pay studies in the health care and transport sectors.
He has published more than 200 articals and reports in health economics and economics of transport safety.
Ulf Persson has 10 years experience as a member of the board of the Swedish pricing and reimbursement authority, the Pharmaceutical Benefit Board (former LFN) and at the Swedish Dental Benefit Board, both included in the Dental and Pharmaceutical Benefits Agency (TLV).
Selected publications
Ghatnekar O, Bondesson O, Persson U & Eriksson T
Health economic evaluation of the Lund Integrated Medicines Management Model (LIMM) in elderly patients admitted to hospital
BMJ Open 2013;3:e001563
Norlin J M, Steen Carlsson K, Persson U & Schmitt-Egenolf M
Switch to Biological Agent in Psoriasis Significantly Improved Clinical and Patient-Reported Outcomes in Real-World Practice
Dermatology Published Online First: January 16, 2013
Asseburg C, Willis M, Löthgren M, Seppälä N, Hakala M & Persson U
Hospitalisation Utilisation and Costs in Schizophrenia Patients in Finland before and after Initiation of Risperidone Long-Acting Injection
Schizophrenia Research and Treatment. 2012; Volume 2012, Article ID 791468, 9 pages
Borg S, Näslund I, Persson U & Ödegaard K
Budget impact analysis of surgical treatment for obesity in Sweden
Scandinavian Journal of Surgery 2012; 101(3): 190–197
Lökk J, Persson U & Wainwright M
Social and Economic Benefits of Early Optimised Treatment for Parkinson´s Disease Patients - Improved Quality of Life and Greater Productivity
European Neurological Review 2012; 7(2): 113-117
Foreword by Susanna Lindvall
Persson U, Svensson J & Pettersson B.
A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing.
Applied Health Economics and Health Policy, 2012; 10(4): 217-25
Svensson J, Ghatnekar O, Lindgren A, Lindvall O, Norrving B, Persson U & Kokaia Z.
Societal Value of Stem Cell Therapy in Stroke - A Modeling Study.
Cerebrovascular Diseases, 2012; 33(6): 532-539
Olofsson S, Wickström A, Glenngård A H, Persson U & Svenningsson A
Effect of treatment with Natalizumab on ability to work in people with Multiple Sclerosis – productivity gain based on direct measurement of work capacity before and after 1 year of treatment
BioDrugs, 2011; 25 (5): 299-306
Nuijten MJ, Mittendorf T and Persson U
Practical issues in handling data input and uncertainty in a budget impact analysis
Eur J Health Econ. 2011; 12(3): 231-241
Hjortsberg C & Persson U
The Value of Informal Caregiver Time for Psychotic Illness
The Journal of Mental Health Policy and Economics, 2010; 13(3): 127-133
Mittendorf T, Briggs A, Bastida J L, Nuijten M & Persson U
Do Health Politicians Really Listen to Health Economists? - Observations from Europe
ISPOR Connections November/December 2009; 15(6): 15-16
Borg S, Persson U, Jess T, Thompsen O, Ljung T, Riis L & Munkholm P.A
Maximum likelihood estimator of a Markov model for disease activity in Crohn´s disease and ulcerative colitis for annually aggregated partial observations
Medical Decision Making, 2010 Jan-Feb; 30(1): 132-142
Romé Å, Persson U, Ekdahl C & Gard G
Willingness to pay for health improvements of physical activity on prescription
Scandinavian Journal of Public Health, 2010; 38(2): 151-159
Persson U, Willis M & Ödegaard K
A case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in Sweden
The European Journal for Health Economics 2010 April; 11(2): 195-203
Willis M, Svensson M, Löthgren M, Eriksson B, Berntsson A & Persson U
The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden
The European Journal of Health Economics, 2010; 11(6): 585-594
Willis M, Persson U, Zoellner Y & Gradl B
Reducing uncertainty in value-based pricing using evidence development agreements: the case of continuous intraduodenal infusion of levodopa/carbidopa (Duodopa®) in Sweden
Applied Health Economics and Health Policy, 2010; 8(6): 377-86
Glenngård A H & Persson U
Costs associated with sharps injuries in the Swedish health care setting and potential cost savings from needle-stick prevention devices with needle and syringe
Scand J Infect Dis. 2009; 41(4): 296-302
Bergman A, Hjelmgren J, Ortqvist A, Wisloff T, Sonbo Kristiansen I, Diaz Hogberg L, M-S Persson K, Persson U
Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden
Scand J Infect Dis. 2008;40(9):721-9
Glenngård A H, Persson U & Schön S
Cost-effectiveness analysis of treatment with epoietin-alpha for patients with anaemia due to renal failure: The case of Sweden
Scandinavian Journal of Urology and Nephrology. 2008;42(1):66-73
Odegaard K, Borg S, Persson U, Svensson M
The Swedish cost burden of overweight and obesity - evaluated with the PAR approach and a statistical modelling approach
International Journal of Pediatric Obesity. 2008;3 Suppl 1:51-7
Borg S, Glenngård AH, Österborg A & Persson U
The cost-effectiveness of treatment with erythropoietin compared to red blood cell transfusions for patients with chemotherapy induced anaemia: A Markov model
Acta Oncologica 2008; 47(6):1009-1017
Tunsäter A, Moutakis M, Borg S, Persson U, Strömberg L & Nielsen AL
Retrospective incremental cost analysis of a hospitalbased COPD Disease Management Programme in Sweden
Health Policy 2007;81:309-319
Borg S, Persson U, Allikmets K & Ericsson K
Comperative Cost-Effectiveness of Anticoagulation with Bivalirudin or Heparin With or Without Glycoprotein IIb/IIIa-Receptor Inhibitor in Patients Undergoing Percutaneous Coronary Intervention in Sweden: A Decision- Analytic Model
Clinical Therapeutics 2006;28(11):1947-1959
Hjelmgren J, Ghatnekar O, Reimer J, Grabowski M, Lindvall M, Persson U & Hagell P
Estimating the value of novel interventions for Parkinson’s disease: A nearly decision-making model with application to dopamine cell replacement
Parkinsonism and Related Disorders 12(2006) 443–452
Borg S, Persson U, Ödegaard K, Berglund G, Nilsson J-Å & Nilsson Peter M.
Obesity, survival and hospital costs - findings from a screening project in Sweden.
Value in Health 2005; 8(5): 562-571.
Persson U, Borg S, Jansson S, Ekman T, Franksson L, Friesland S & Larsson A-M.
Epoetin alfa and Darbepoetin alfa for the Treatment of Chemotherapy-Related Anemia in Cancer Patients in Sweden: Comparative Analysis of Drug Utilization, Costs, and Hematologic Response.
Advances in Therapy 2005; 22(3): 208-224.
Anell A & Persson U
Reimbursement and clinical guidance for pharmaceuticals in Sweden * Do health economic evaluations support decision-making? The European Journal of Health Economics 2005 6(3); 274-279.
Magnusson G & Persson U
Screening for congenital cataracts: a cost-consequence analysis of eye-examination at maternity wards in comparison to well-baby clinics. Acta Paediatrica 2005; 94: 1089-95.
Hjelmgren J, Persson U & Ragnarsson Tennvall G.
Local treatment pattern versus trial-based data: A cost-effectiveness analysis of drotrecogin alfa (activated) in the treatment of severe sepsis in Sweden.
American Journal of Therapeutics 2005; 12(5): 425-430.
Glenngård A H, Persson U & Söderman C. Costs Associated with Blood Transfusions in Sweden – The societal cost of autologous, allogeneic and perioperative RBC transfusion. Transfusion Medicine 2005; 15(4): 295-306.
Ghatnekar O, Persson U, Glader E-L & Terént A
Cost of stroke in Sweden: An incidence estimate.
International Journal of Technology Assessment in Health Care, 2004; 20(3): 375-380
Magnusson G & Persson U
Screening for congenital cataracts: a cost-cosequence analysis of eye-examination at maternity wards in comparison to well-baby clinics.
Manuscript in Magnusson G. On the Necessity of Screening and National Registration of Congenital Cataracts (doctoral dissertation).
Göteborg: Göteborg University, April 16, 2004.
Persson U
Valuing Reductions in the Risk of Traffic Accidents Based on Empirical Studies in Sweden (Doctoral dissertation, February 27, 2004).
Lund: Department of Technology and Society. Lund Institute of Technology, Lund University, Bulletin 222; 2004.
Hjelmgren J, Ceberg J, Persson U & Alvegård TA.
The cost of treating pancreatic cancer - a cohort study based on patients records from four hospitals in Sweden.
Acta Oncologica 2003; 42(3): 218-26
Hjalte K, Norinder A, Persson U & Maraste P.
Health-health analysis - An alternative method for economic appraisal of health policy and safety regulation: Some Swedish estimates
Accident Analysis and Prevention 2003; 35: 37-46
Maraste P, Persson U & Berntman M.
Long-term follow-up and consequences for severe road traffic injuries - Treatment costs and health impairment in Sweden in the 1960s and the 1990s.
Health Policy 2003
Hjelmgren J, Ceberg J, Persson U & Alvegård TA.
The cost of treating pancreatic cancer - A cohort study based on patient records from four hospitals in Sweden.
Acta Oncologica 2002
Persson U & Ghatnekar O.
Cost-effectiveness analysis of inhaled corticosteroids in asthma - A review of the analytical standards
Respiratory Medicine, 2003; 97(1); 1-11
Ödegaard K, Nilsson JÅ, Persson U, Nilsson P & Berglund G.
Obesity and potential cost offsets from weight loss - Findings from the Swedish Malmö prevention study
Value in Health 2002:5(no 6); 464.
P Hagell, S Nordling, J Reimer, M Grabowski & U Persson
Resource Use and Costs in a Swedish Cohort of Patients with Parkinson's Disease
Movement Disorders Vol. 17, No. 6, 2002, pp. 1213*1220
A Norinder, U Persson, P Nilsson, J-Å Nilsson, B Hedblad & G Berglund
Costs for screening, intervention and hospital treatment generated by the Malmö Preventive Project: a large-scale screening programme.
Journal of Internal Medicine 2002; 25:44-52
O Ghatnekar, M Willis & U Persson
Cost-effectiveness of treating deep diabetic foot ulcers with Promogran in four European countries
Journal of Wound Care, vol 11, no 2, February 2002
Persson U, Norinder A, Hjalte K & Gralén K
The value of a statistical life in transport: Findings from a new contingent valuation study in Sweden.
The Journal of Risk and Uncertainty, 23:2; 121-134, 2001.
Willis M., Ödegaard K., Persson U., Hedbrant J., Mellström D. & Hammar M
A cost-effectiveness model of tibolone as treatment for the prevention of osteoporotic fractures in postmenopausal women in Sweden.
Clin Drug Invest 2001; 21 (2): 115-127
Ghatnekar, O., Persson, U., Willis, M., Wright, T. & Ödegaard, K.
The cost-effectiveness in the UK of treating diabetic lower extremity ulcers with becaplermin gel.
Journal of Drug Assessment 2000;3: 235-286
Persson U.
Pharmacoeconomics in new pharmaceutical development in Sweden.
SIAR News 2000:30;48-50.
Persson U & Malmberg I.
Primärvårdskostnaderna för behandling av hjärtsvikt kartlagda - Ökad användning av ACE-hämmare skulle löna sig.
Läkartidningen 2000:97(20);2465-2470.
Author Ulf Persson
Painful Bone Metastases in Hormone Refractory Prostate Cancer. Economic Costs of Strontium-89 an/or External Radiotherapy(er).
Urology 1997 (in press).
(with Malmberg I, Ask A, Tennvall J, Abrahamsson P-A)
Cost of long-term complications of deep venous thrombosis of the lower extremities: An Analysis of a Defined Patient Population in Sweden.
Annals of Internal Medicine 1997;126:454-457
(with Bergqvist D, Jendteg S, Johansen L, Ödegaard K).
Guidelines for Health Economic Evaluations: Is this anything for Sweden?
Läkartidningen 1997;94,No.24:2289-2292 (in Swedish).
Group Living for Elderly Patients with Dementia- A Cost Analysis.
Health Policy 1996:38;83-100)
(with Svensson M, Edebalk PG)
Cost per fatal and non-fatal traffic injuries in Europe: How can you explain the differences in unit costs? In Monetarisation des conséquences des accidents de la route.
Coordination éditoriale, Institute National de Recherche sur les Transports et leur Sécurité, Paradigme Orléans, 1996.
"Valuing the Benefits of Reducing the Risk of Non- Fatal Road Injuries: The Swedish Experience". In Schwab Christe N. and Soguel N. (eds.) "Contingent Valuation, Transport Safety and the Value of Life.
Studies in Risk and Uncertainty.
Kluwer Academic Publishers, 1995
(with Norinder A, Svensson M) .
External Cost Estimates of Road Traffic Accidents- An International Comparison.
Journal of Transport Economics and Policy 1995 September:291-304
(with Ödegaard K.).
The Indirect Costs of Morbidity in Type II Diabetic Patients.
PharmacoEconomics 1995;8(suppl 1):28-32.
"Socio-economic cost of road accidents. COST 313". In Alfaro J-l, Chapuis M, Fabre F (eds), European Commission.
Final report of the action COST 313. Luxembourg: Office for Official Publications of the European Communities, 1994.
Comparison of Excess Costs of Care and Production Losses Because of Mor-bidity in Diabetic Patients.
Diabetes Care 1994; 17,No.11: 1257-1263
(with J. Olsson, C. Tollin, S. Nilsson and A. Melander).
Lönar sig förebyggande åtgärder? Exempel från hälso- och sjukvården och trafiken. (Preventive Measures - are they Profitable? Example from the the Health Service and the Traffic).
Rapport till ESO, Finansdepartementet, Ds 1993:337.
Three approaches to valuing benefits of traffic safety measures.
IHE monograph, 1992 (dissertation).
Cost-effectiveness analysis of treatment with liposomal amphotericin B versus con-ventional amphotericin B in organ or bone marrow transplant recipients.
Pharmaco-Economics 1992:2, 500-508
(with G. Ragnarsson Tennvall, S. Andersson, G. Tydén and B. Wettermark).
Cost-effectiveness of Simvastatin versus Cholestyramine - Results for Sweden.
PharmacoEconomics 1992:2, 110-114
(with K. Hjalte and B. Lindgren).
Home Service Costs: The Swedish Experience.
Health Policy 1991:19, 197-209
(with Marianne Svensson and Per Gunnar Edebalk).
EuroQol - A new Facility for the Measurement of Health-Related Quality of Life.
Health Policy 1990 (16): 199-208
(with Alan Williams, Martin Buxton et. al.).
Screening for Scoliosis. A Cost-Effectiveness Analysis.
Spine 1990 (15): 67-70
(with Fredrik Montgomery, Björn Lindgren, Göran Benoni and Stig Willner).
Direct Costs of Stroke for a Swedish Population.
International Journal of Techno-logy Assessment in Health Care 1990 (6): 125-137
(with Björn Lindgren, Raymunda Silverberg, Barbro Johansson et. al.)
The Cost-Effectiveness of a New Antihypertensive Drug, Doxazosin.
Current The-rapeutic Research 1989:45 nr 5, 738-769; 23 pp
(with Björn Lindgren).
How Far does Prophylaxis against Infection in Total Joint Replacement Offset its Costs?.
British Medical Journal 1988 (296), 99-102
(with Fredrik Montgomery, Åke Carlsson, Björn Lindgren and Lennart Ahnfelt).
Publications in Swedish, please go to Ulf Perssons Swedish site.